Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Summary
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European UnionApproval based on strength of data from two pivo...
Description
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European UnionApproval based on strength of data from two pivo...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source